The FLI was initially designed to assist in identifying patients who may have Non-Alcoholic Fatty Liver Disease (NAFLD) (1–6), and has been validated as an effective tool for recognizing characteristics of liver fat accumulation associated with various metabolic disorders, such as insulin resistance, inflammation, and oxidative stress (7). This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.